Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:MRNA News 8 October 2025 - 7 January 2026

Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna shares fell 1.4% to $35.15 premarket Wednesday after a 10.9% surge Tuesday, following news it filed for approval of its mRNA flu vaccine in the U.S., Europe, Canada, and Australia. The company reported 26.6% relative efficacy for the vaccine in adults 50 and older. Bayer’s Monsanto unit sued Moderna and other COVID-19 vaccine makers Tuesday, alleging mRNA patent infringement.
7 January 2026
··
Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

The Dow Jones closed above 49,000 for the first time Tuesday, ending at 49,462.08, up 1%. Chip and healthcare stocks led gains, with Moderna jumping nearly 11% and the PHLX semiconductor index hitting a record. Data-storage shares surged, while Nvidia and AMD slipped after CES presentations. Investors await Wednesday’s JOLTS and Friday’s U.S. jobs report for rate clues.
6 January 2026
······
Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

The Dow hit a record high Tuesday, rising 1.02% to 49,476.54 as chip and healthcare shares led gains. SanDisk surged 23% on AI hardware optimism tied to CES, while Johnson Controls fell 7.5% after Nvidia’s chip announcement. Investors monitored U.S. jobs data and Fed signals following gaps caused by last year’s federal shutdown.
6 January 2026
············
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna shares fell 4.73% to $31.20 Friday, closing out a volatile holiday week with no major company news or FDA headlines in the past 48 hours. After-hours trading edged lower near $31.10. Barron’s and MarketBeat flagged the stock’s sharp move and heavy trading volume. Analyst commentary focused on technicals and sector positioning rather than new fundamentals.
28 December 2025
··
Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts

Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts

NEW YORK — Dec. 26, 2025 (1:18 p.m. ET) — Moderna, Inc. (NASDAQ: MRNA) shares were trading at about $31.31, down roughly 4.4% on the day, in a notably quiet, post-holiday session where low liquidity can exaggerate moves in individual names. The pullback comes even as the broader market hovers near record territory during the so-called “Santa Claus rally” window, with investors balancing year-end positioning against a steady drumbeat of vaccine-policy headlines and pipeline expectations that will shape 2026 for vaccine makers like Moderna. Reuters+1 Moderna stock price today: the quick snapshot As of early afternoon in New York: Today’s
26 December 2025
··
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

December 24, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending 2025 with the kind of chart action that makes both traders and long-term biotech investors sit up straight. After a sharp multi-day run, Moderna stock pulled back hard: shares closed at about $32.29 on Dec. 23, down ~7.48% on the day, and were indicated around $32.11 in pre-market trading on Dec. 24. StockAnalysis That drop matters—but so does the context. The pullback follows a late-December surge that coincided with multiple headlines touching Moderna’s near-term product story (respiratory vaccines), its longer-term optionality (oncology and next-gen platforms), and its financial runway (new
24 December 2025
··
Moderna Stock (MRNA) Drops on Dec. 23, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next

Moderna Stock (MRNA) Drops on Dec. 23, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching Next

December 23, 2025 — Moderna, Inc. (NASDAQ: MRNA) shares slid sharply in Tuesday trading, pulling back after a powerful multi-day run that had pushed the biotech back into the mid-$30s. By the latest available intraday quote, MRNA was trading around $32.7, down roughly 6% on the day, after closing at $34.90 on Monday. StockAnalysis The decline lands amid a busy stretch of late-2025 headlines for Moderna—spanning pandemic preparedness funding, European regulatory progress for its next-generation COVID shot, shifting U.S. vaccine policy, and a deal aimed at improving how some future Moderna medicines might be delivered. Here’s what’s driving the stock
23 December 2025
·
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

December 20, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending the year in classic Moderna fashion: a tug-of-war between near-term uncertainty (COVID policy and demand) and long-term optionality (a pipeline that still wants to be the sequel to the pandemic-era blockbuster). The stock last traded around $33.80, up roughly 9% from the prior close, with a market cap near $13 billion and a 52-week range roughly $22–$49. Investing.com That jump comes as investors digest a fresh burst of pandemic-preparedness funding tied to Moderna’s H5 bird flu program—while, at the same time, headlines swirl around potential FDA actions on COVID-19 vaccine
20 December 2025
·
Moderna (MRNA) Stock on 8 December 2025: Institutional Tug‑of‑War, FDA Shockwaves and 2026–2030 Forecasts

Moderna (MRNA) Stock on 8 December 2025: Institutional Tug‑of‑War, FDA Shockwaves and 2026–2030 Forecasts

Published: 8 December 2025 – all data and news current to this date. This article is informational only and not investment advice. Key takeaways Where Moderna stock stands today As of 8 December 2025, Moderna shares trade around $27.70, roughly flat after a powerful rebound that saw the stock jump 8–9% on 5 December on heavy volume. StockInvest+1 Over the last year the stock has: The result is a mid‑cap biotech with: On pure price action, MRNA is still in a long, downward trend from its pandemic peak, but the last few weeks have featured: This volatility is being driven
8 December 2025
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna Inc. (NASDAQ: MRNA) is back in the spotlight. After months of pressure from collapsing COVID‑19 vaccine demand and rising regulatory scrutiny, the stock has staged a sharp rebound in early December 2025 — powered by a major long‑term safety study from France and a new $1.5 billion credit facility. Here’s a deep dive into the latest news, forecasts, and analyses around Moderna stock from December 6, 2025 onward, and what they collectively suggest for the company’s risk‑reward profile. Moderna stock today: sharp bounce, still bruised As of the close on December 5, 2025, Moderna shares finished at $27.70, up
6 December 2025
··
Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Updated: December 6, 2025 Moderna, Inc. (NASDAQ: MRNA) has just had one of its most dramatic weeks of 2025. Shares plunged early in the week after news that the U.S. Food and Drug Administration (FDA) may tighten vaccine approval standards, then rebounded sharply on Friday after a massive French real‑world study reaffirmed the safety and effectiveness of its COVID‑19 vaccine. Investopedia+2Investopedia+2 As of the close on Friday, December 5, Moderna stock finished at $27.70, up 8.7% on the day and trading near the middle of its 52‑week range of $22.28 to $48.92, giving the company a market capitalization of about
6 December 2025
Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. (NASDAQ: MRNA) enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out a new three‑year strategy, taking on $1.5 billion in debt, cutting pipeline projects and doubling down on its mRNA platform in respiratory disease and cancer. Reuters+3Financial Times+3Barron’s+3 Here’s a detailed look at Moderna stock today, what changed this week, and how the latest headlines might shape the risk–reward for investors. Moderna stock price snapshot for November 23, 2025 U.S. markets
23 November 2025
·
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity boost, strategy reset and manufacturing push Moderna, Inc., the mRNA‑vaccine pioneer behind Spikevax®, is back in the spotlight today after unveiling a trio of significant updates on November 20, 2025: The moves come as Moderna tries to navigate a steep post‑pandemic revenue reset, heavy R&D spending and investor skepticism about how quickly its broad mRNA pipeline can translate into sustainable
20 November 2025
··
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. (NASDAQ: MRNA) posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0 billion, cut operating‑expense guidance, and raised its year‑end cash outlook. Shares popped in pre‑market trading before wobbling intraday. SEC+1 What happened Moderna’s Q3 print outpaced expectations on both the top and bottom lines, led by stronger‑than‑modeled sales of its updated COVID‑19 shot (marketed this season as mNEXSPIKE/Spikevax 2025–26). Management simultaneously tightened the full‑year revenue band and lowered operating‑expense plans, signaling
6 November 2025
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 19.10.2025

ENDEDLive coverage has endedEnded: October 21, 2025, 6:00 AM EDT IonQ vs Nvidia: Which AI Stock Has the Better Long-Term Upside? October 20, 2025, 5:58 AM EDT. IonQ offers long-term AI potential through quantum computing, with room-temperature operation and growing partnerships such as Oak Ridge National Laboratory. Its recent Q3 results showed revenue up 102% YoY to $12.4 million and $63.5 million in new bookings, but the firm remains unprofitable, posting a net loss of $52.5 million as it spends on R&D and pursues growth, including the Qubitekk acquisition to build a networked quantum ecosystem. Nvidia remains the more established
19 October 2025
···········
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus Day holiday), the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior sessionstockinvest.us. Technical analysts at Stockinvest.us noted the shares were near the upper part of a wide falling trend and predicted a possible trading range of $26.40–$28.73 on Oct 8, with longer‑term support around $26 and resistance near $31stockinvest.us. While short‑term signals were positive, they cautioned that the overall downward trend remainsstockinvest.us. Because multiple financial
8 October 2025
··
1 2

Stock Market Today

IHC stock price holds near 400 dirhams after Abu Dhabi group flags phishing emails

IHC stock price holds near 400 dirhams after Abu Dhabi group flags phishing emails

7 February 2026
Abu Dhabi, Feb 8, 2026, 01:14 (GST) — Market closed. International Holding Company PJSC (IHC.AD) warned investors about phishing emails and online approaches using the company’s name and branding, an Abu Dhabi Securities Exchange disclosure showed, after its shares ended Friday unchanged at 399.60 dirhams. (ADX) The notice landed into a market that is trading headlines again. UAE stocks closed slightly higher on Friday as investors tracked Iran-U.S. negotiations on Tehran’s nuclear programme and moves in oil prices. (Reuters) That matters because the bigger tone has been “risk on”, but it has been brittle. A few lines out of Muscat,
Go toTop